Scientists have found that neuroangiostrongyliasis combination therapy using albendazole and doxycycline offers superior neuroprotection. Angiostrongylus cantonensis causes eosinophilic meningitis, a condition often seen in parts of Southern India. Although clinicians use albendazole to kill larvae, the drug often worsens inflammation via antigen release. Therefore, researchers investigated whether doxycycline could mitigate this effect through its anti-inflammatory properties.

The study demonstrated that early combination therapy effectively eliminates parasites. Moreover, it reduces perivascular inflammation and hemorrhagic changes. Consequently, the dual approach provides a more stable recovery than monotherapy.

MRI Evidence for Neuroangiostrongyliasis Combination Therapy

Using high-resolution MRI, the team observed a marked decrease in brain hyperintensity. This finding indicates that the treatment prevents extensive cerebral edema. Additionally, biochemical analysis showed a restoration of the IL-33/GFAP balance. Because these markers signify astrocyte and microglial activation, their normalization confirms reduced neuroinflammation.

Furthermore, serological tests showed lower immunoglobulin levels in the treated groups. This suggests that the combination therapy modulates the systemic immune response. Therefore, these findings support the use of doxycycline as a neuroprotective adjunct in parasitic meningitis. Notably, the treatment window is critical, as early intervention yielded the most consistent improvements. Similarly, the study highlights the importance of glial regulation in managing parasitic brain injuries. In addition, the reduction in specific IgA/G/M reactivity proves that the therapy affects multiple immune pathways. Thus, this regimen may become a future standard for managing rat lungworm disease.

FAQ

Why is doxycycline added to albendazole in this therapy?

Doxycycline acts as a neuroprotective agent. It attenuates glial activation and matrix metalloproteinase activity, which reduces the inflammation caused by dying parasites. This helps prevent the clinical worsening often seen with anthelmintic monotherapy.

What markers of neuroinflammation are affected by this treatment?

The therapy restores the balance of interleukin (IL)-33 and glial fibrillary acidic protein (GFAP). These markers are typically elevated during astrocyte and microglial activation. Normalizing these levels indicates a reduction in brain-wide inflammatory damage.

Is this treatment currently approved for human use?

While albendazole is a standard treatment, this specific combination is currently supported by preclinical mouse models. These findings provide a strong rationale for future clinical trials to confirm its safety and efficacy in humans suffering from neuroangiostrongyliasis.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Jhan KY et al. Albendazole-doxycycline combination therapy alleviates MRI- and pathology-evident neuroinflammation and restores IL-33/GFAP balance in mouse neuroangiostrongyliasis. Parasit Vectors. 2026 Feb 06. doi: 10.1186/s13071-026-07284-6. PMID: 41652430.

Chotmongkol V, et al. Efficacy of albendazole plus prednisolone versus prednisolone alone in treatment of helminthic eosinophilic meningitis. Trans R Soc Trop Med Hyg. 2009;103(4):346-349.

Murphy GS and Johnson S. Clinical aspects of Eosinophilic Meningitis and Meningoencephalitis caused by Angiostrongylus cantonensis, the Rat lungworm. Hawai'i Journal of Medicine & Public Health. 2013;72(6 Suppl 2):35-40.